Compare · SIBN vs SYK
SIBN vs SYK
Side-by-side comparison of SI-BONE Inc. (SIBN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SIBN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 144.8x SIBN ($875.8M).
- SIBN has been more active in the news (14 items in the past 4 weeks vs 9 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- SI-BONE Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $875.8M
- $126.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 14
- 9
- Recent ratings
- 12
- 25
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SIBN
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $1,088,201 worth of shares (55,807 units at $19.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Op & Financial Officer Maheshwari Anshul sold $337,138 worth of shares (16,975 units at $19.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 234,920 units (SEC Form 4)
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $279,065 worth of shares (14,956 units at $18.66), decreasing direct ownership by 2% to 493,900 units (SEC Form 4) (tax liability)
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $69,411 worth of shares (3,725 units at $18.63), decreasing direct ownership by 1% to 273,650 units (SEC Form 4) (tax liability)
- Chief Financial Officer Maheshwari Anshul sold $87,016 worth of shares (4,665 units at $18.65), decreasing direct ownership by 2% to 251,895 units (SEC Form 4) to cover withholding tax
- SEC Form SCHEDULE 13G filed by SI-BONE Inc.
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $369,214 worth of shares (20,000 units at $18.46) as part of a pre-agreed trading plan (SEC Form 4)
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation